Tien Hoang

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. doi request reprint Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study
    Tien Hoang
    University of Wisconsin Carbone Cancer Center, Madison, WI, USA
    Invest New Drugs 32:195-9. 2014
  2. doi request reprint Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594
    Tien Hoang
    Hematology Oncology Section, University of Wisconsin, Wisconsin Institutes for Medical Research, Madison, WI 53705, USA
    Lung Cancer 81:47-52. 2013
  3. pmc Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab
    Tien Hoang
    Department of Medicine, University of Wisconsin, Madison, Wisconsin 53705, USA
    J Thorac Oncol 7:1361-8. 2012
  4. pmc Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study
    Tien Hoang
    Wisconsin Institute for Medical Research, 1111 Highland Ave, Madison, WI 53705, USA
    J Clin Oncol 30:616-22. 2012
  5. ncbi request reprint Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data
    Tien Hoang
    University of Wisconsin Medical School, 600 Highland Ave, K4 562, Madison, WI, USA
    J Clin Oncol 23:175-83. 2005
  6. ncbi request reprint Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy
    Tien Hoang
    Department of Medicine, University of Wisconsin Medical School, Madison 53792, USA
    Expert Rev Anticancer Ther 2:393-401. 2002
  7. pmc Enhancement of radiation response with bevacizumab
    Tien Hoang
    Department of Medicine, University of Wisconsin Madison, Madison, WI, USA
    J Exp Clin Cancer Res 31:37. 2012
  8. pmc Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer
    Shannon E O'mahar
    Department of Medicine, Division of Hematology and Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53705, USA
    J Thorac Oncol 6:951-3. 2011
  9. pmc Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States
    Lung Cancer 64:51-9. 2009
  10. pmc Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin, USA
    J Thorac Oncol 3:1018-25. 2008

Detail Information

Publications15

  1. doi request reprint Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study
    Tien Hoang
    University of Wisconsin Carbone Cancer Center, Madison, WI, USA
    Invest New Drugs 32:195-9. 2014
    ..Conclusions Bortezomib and vorinostat displayed minimal anti-tumor activity as third-line therapy in NSCLC. We do not recommend this regimen for further investigation in unselected patients. ..
  2. doi request reprint Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594
    Tien Hoang
    Hematology Oncology Section, University of Wisconsin, Wisconsin Institutes for Medical Research, Madison, WI 53705, USA
    Lung Cancer 81:47-52. 2013
    ..We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen...
  3. pmc Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab
    Tien Hoang
    Department of Medicine, University of Wisconsin, Madison, Wisconsin 53705, USA
    J Thorac Oncol 7:1361-8. 2012
    ....
  4. pmc Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study
    Tien Hoang
    Wisconsin Institute for Medical Research, 1111 Highland Ave, Madison, WI 53705, USA
    J Clin Oncol 30:616-22. 2012
    ..The primary objective of this study was to compare the survival of patients with unresectable stage III non-small-cell lung cancer (NSCLC) treated with combined chemoradiotherapy with or without thalidomide...
  5. ncbi request reprint Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data
    Tien Hoang
    University of Wisconsin Medical School, 600 Highland Ave, K4 562, Madison, WI, USA
    J Clin Oncol 23:175-83. 2005
    ....
  6. ncbi request reprint Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy
    Tien Hoang
    Department of Medicine, University of Wisconsin Medical School, Madison 53792, USA
    Expert Rev Anticancer Ther 2:393-401. 2002
    ..These novel agents target molecular pathways specifically found in cancer cells, thus maximizing the antitumor effect while minimizing toxicities on normal cells...
  7. pmc Enhancement of radiation response with bevacizumab
    Tien Hoang
    Department of Medicine, University of Wisconsin Madison, Madison, WI, USA
    J Exp Clin Cancer Res 31:37. 2012
    ..Bevacizumab is a humanized monoclonal antibody that neutralizes VEGF. We examined the impact on radiation response by blocking VEGF signaling with bevacizumab...
  8. pmc Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer
    Shannon E O'mahar
    Department of Medicine, Division of Hematology and Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53705, USA
    J Thorac Oncol 6:951-3. 2011
    ..We conducted a dose escalation study of this combination to determine the maximum tolerated dose of sunitinib in combination with a fixed dose of erlotinib and to evaluate the toxicities of this combination...
  9. pmc Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States
    Lung Cancer 64:51-9. 2009
    ..The safety and tolerability of combination therapy with the EGFR inhibitor, gefitinib, and fulvestrant was explored...
  10. pmc Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin, USA
    J Thorac Oncol 3:1018-25. 2008
    ..Vinorelbine is safe and effective in older patients with advanced NSCLC. We assessed these agents together as palliative treatment for older patients with advanced NSCLC...
  11. pmc Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer
    Anne M Traynor
    Department of Medicine and Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Lung Cancer 81:138-41. 2013
    ..We sought to determine if protein expression of nEGFR is prognostic in early stage non-small cell lung cancer (NSCLC)...
  12. ncbi request reprint Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer
    Tien Hoang
    Room K4 538, Clinical Science Center, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
    Lung Cancer 42:97-102. 2003
    ..Eligibility criteria included prior treatment with only one chemotherapy regimen and Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients with brain metastases were eligible...
  13. doi request reprint Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes
    Jill M Kolesar
    University of Wisconsin Carbone Comprehensive Cancer Center, 600 Highland Avenue, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 72:661-7. 2013
    ..Vorinostat is a small molecule inhibitor of class I and II histone deacetylase enzymes which alters the expression of target genes including the cell cycle gene p21, leading to cell cycle arrest and apoptosis...
  14. doi request reprint A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies
    William R Schelman
    University of Wisconsin Carbone Cancer Center, 600 Highland Avenue, K6 568 CSC, Madison, WI, 53792, USA
    Invest New Drugs 31:1539-46. 2013
    ..A phase I study to assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK) and antitumor activity of vorinostat in combination with bortezomib in patients with advanced solid tumors...
  15. ncbi request reprint Novel therapies for lung cancer
    Tien Hoang
    Department of Medicine, Medical Oncology, University of Wisconsin Medical School, Madison, WI 53792, USA
    Surg Oncol 11:229-41. 2002
    ....